Document is current

Article History

Received: 20 May 2023

Accepted: 11 June 2023

First Online: 28 June 2023

Declarations

:

: Rebecca D. Chernock has a non-financial relationship with Caris Life Sciences as a member of their Precision Oncology Alliance and is a member of the Steering Committee for a Phase III clinical trial of neoadjuvant Pembrolizumab in surgically resectable, locally advanced head and neck squamous cell carcinoma (MK-3475-689), Merck & Co., Inc. Brian A. Van Tine has research grants or contracts from Pfizer, Merck, Tracon Pharm, GSK and Polaris; a has a license for a patent from Accuronix Therapeutics; received consulting fees from Cytokinetics Inc, Bayer, Deciphera Pharmaceuticals, Daiichi Sanko Inc, EcoR1, Advenchen, Putnam, Salarius Pharmaceuticals Inc., Boxer Capital LLC, Acuta Capital Partners, LLC and Aadi; received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Iterion Therapeutics, Inc. and Total Health Conference; received payment of expert testimony from Anderson and Reynolds PLC; received support for attending meetings or travel from Adaptimmune; has planned, issued or pending patents on ALEX3102 and the use of ME1 as a biomarker; participated on data safety monitoring or advisory boards for Apexigen, INC, Daiichi Sankyo, Epizyme, Bayer US Medical Affairs Oncology, PTC Therapuetics, Aadi Biosciences, Boehringer Ingelheim, Agenus, Regeneron Pharmaceuticals, Advenchen, EcoR1 Captial, LLC and Curis; and is a board member at Polaris.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The institutional review board (IRB) determined that no human research was performed for this descriptive case report.

: For this type of study informed consent is not required.

: For this type of study consent for publication is not required.